We are live on ! Find out more
IPXL

Impax Laboratories, Inc.
IPXL

Delisted

IPXL was delisted on the 4th of May, 2018.

178 hedge funds and large institutions have $2.03B invested in Impax Laboratories, Inc. in 2014 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 59 increasing their positions, 62 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 18

46% more call options, than puts

Call options by funds: $8.42M | Put options by funds: $5.76M

44% more capital invested

Capital invested by funds: $1.42B → $2.03B (+$617M)

10% more funds holding

Funds holding: 162178 (+16)

5% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 62

Holders
178
Holders Change
+16
Holders Change %
+9.88%
% of All Funds
4.75%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
37
Increased
59
Reduced
62
Closed
18
Calls
$8.42M
Puts
$5.76M
Net Calls
+$2.66M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$212M +$7.98M +272,800 +4%
BFA
2
BlackRock Fund Advisors
California
$159M +$9.35M +319,336 +7%
Vanguard Group
3
Vanguard Group
Pennsylvania
$145M +$2.93M +100,224 +2%
Invesco
4
Invesco
Georgia
$105M -$7.89M -269,645 -8%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$95.7M +$21.1M +722,200 +31%
Franklin Resources
6
Franklin Resources
California
$79.6M +$50.1M +1,710,274 +213%
State Street
7
State Street
Massachusetts
$77.6M -$7.97M -272,255 -10%
SPC
8
Slate Path Capital
New York
$73.8M
AG
9
Aravt Global
New York
$72.9M +$67.3M +2,300,000 New
UBS AM
10
UBS AM
Illinois
$66.6M -$3.8M -129,935 -6%
BIT
11
BlackRock Institutional Trust
California
$57.2M -$911K -31,138 -2%
Ameriprise
12
Ameriprise
Minnesota
$50.6M +$1.52M +51,865 +3%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$47.3M +$1.94M +66,259 +5%
HCM
14
Highfields Capital Management
Massachusetts
$44.4M
Jennison Associates
15
Jennison Associates
New York
$42.1M +$224K +7,650 +0.6%
Northern Trust
16
Northern Trust
Illinois
$30.6M -$703K -24,009 -2%
NIMC
17
NWQ Investment Management Company
California
$28.7M -$11.5M -392,952 -30%
Morgan Stanley
18
Morgan Stanley
New York
$26.9M +$24.5M +837,655 +6,951%
KCM
19
Kornitzer Capital Management
Kansas
$24.6M +$22.7M +775,700 New
Norges Bank
20
Norges Bank
Norway
$23.2M
PCM
21
Penn Capital Management
Pennsylvania
$22.5M -$5.84M -199,550 -22%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$21.5M +$272K +9,291 +1%
PI
23
Putnam Investments
Massachusetts
$19.6M -$6.53M -223,155 -27%
Victory Capital Management
24
Victory Capital Management
Texas
$18.4M +$17M +580,635 New
VOYA Investment Management
25
VOYA Investment Management
Georgia
$17.8M -$504K -17,227 -3%

IPXL Hedge Fund Activity: Q4 2014 in Review

178 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q4 2014, worth a combined $2.03B — up 44% from $1.42B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new IPXL positions and 18 closed out — a net gain of 19 holders — while 59 added to existing stakes and 62 trimmed.

The largest buyer was Franklin Resources, adding an estimated $50.1M. The largest seller was RS Investment Management, exiting entirely with an estimated $19.2M sold.

  • 178 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q4 2014, up from 162 in Q3 2014.
  • Funds reported $2.03B of Impax Laboratories, Inc. stock for Q4 2014, up 44% quarter-over-quarter.
  • 37 funds opened new Impax Laboratories, Inc. positions in Q4 2014 and 18 closed out, a net change of +19 holders.
  • The largest Impax Laboratories, Inc. buyer in Q4 2014 was Franklin Resources, an estimated $50.1M added.
  • The largest Impax Laboratories, Inc. seller in Q4 2014 was RS Investment Management, an estimated $19.2M sold.

Based on aggregated 13F filings for Q4 2014.